Literature DB >> 25604388

Vasopressin receptor antagonists.

Biff F Palmer1.   

Abstract

Arginine vasopressin (AVP) is the principal hormone involved in regulating the tonicity of body fluids. Less appreciated is the role that AVP plays in a variety of other physiologic functions including glucose metabolism, cardiovascular homeostasis, bone metabolism, and cognitive behavior. AVP receptor antagonists are now available and currently approved to treat hyponatremia. There is a great deal of interest in exploring the potential benefits that these drugs may play in blocking AVP-mediated effects in other organ systems. The purpose of this report is to provide an update on the expanding role of AVP receptor antagonists and what disease states these drugs may eventually be used for.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25604388     DOI: 10.1007/s11906-014-0510-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  76 in total

Review 1.  Treatment of hyponatremia.

Authors:  Richard H Sterns; John Kevin Hix; Stephen Silver
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-09       Impact factor: 2.894

2.  Aldosterone requires vasopressin V1a receptors on intercalated cells to mediate acid-base homeostasis.

Authors:  Yuichiro Izumi; Kahori Hori; Yushi Nakayama; Miho Kimura; Yukiko Hasuike; Masayoshi Nanami; Yukimasa Kohda; Yoshinaga Otaki; Takahiro Kuragano; Masuo Obinata; Katsumasa Kawahara; Akito Tanoue; Kimio Tomita; Takeshi Nakanishi; Hiroshi Nonoguchi
Journal:  J Am Soc Nephrol       Date:  2011-03-17       Impact factor: 10.121

Review 3.  Tolvaptan for the management of syndrome of inappropriate antidiuretic hormone secretion: lessons learned in titration of dose.

Authors:  Andrea C Torres; Edmond P Wickham; Diane M Biskobing
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

Review 4.  The contributions of oxytocin and vasopressin pathway genes to human behavior.

Authors:  Richard P Ebstein; Ariel Knafo; David Mankuta; Soo Hong Chew; Poh San Lai
Journal:  Horm Behav       Date:  2011-12-29       Impact factor: 3.587

Review 5.  Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.

Authors:  E L Los; P M T Deen; J H Robben
Journal:  J Neuroendocrinol       Date:  2010-02-12       Impact factor: 3.627

6.  Vasopressin increases expression of UT-A1, UT-A3, and ER chaperone GRP78 in the renal medulla of mice with a urinary concentrating defect.

Authors:  Qi Cai; Sarah K Nelson; Matthew R McReynolds; Maggie Keck Diamond-Stanic; David Elliott; Heddwen L Brooks
Journal:  Am J Physiol Renal Physiol       Date:  2010-07-28

Review 7.  Vasopressin regulation of blood pressure and volume: findings from V1a receptor-deficient mice.

Authors:  Toshinori Aoyagi; Taka-aki Koshimizu; Akito Tanoue
Journal:  Kidney Int       Date:  2009-08-19       Impact factor: 10.612

8.  Adenylyl cyclase 6 enhances NKCC2 expression and mediates vasopressin-induced phosphorylation of NKCC2 and NCC.

Authors:  Timo Rieg; Tong Tang; Shinichi Uchida; H Kirk Hammond; Robert A Fenton; Volker Vallon
Journal:  Am J Pathol       Date:  2012-11-01       Impact factor: 4.307

9.  Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients.

Authors:  Paul E Marik; Racquel Rivera
Journal:  Pharmacotherapy       Date:  2013-01       Impact factor: 4.705

Review 10.  Review of tolvaptan for autosomal dominant polycystic kidney disease.

Authors:  Brian P Baur; Calvin J Meaney
Journal:  Pharmacotherapy       Date:  2014-04-07       Impact factor: 4.705

View more
  3 in total

1.  Conivaptan and Boric Acid Treatments in Acute Kidney Injury: Is This Combination Effective and Safe?

Authors:  Betül Can; Fatih Kar; Ezgi Kar; Mete Özkoç; Hakan Şentürk; Dilek Burukoğlu Dönmez; Güngör Kanbak; İbrahim Özkan Alataş
Journal:  Biol Trace Elem Res       Date:  2021-10-21       Impact factor: 3.738

2.  Effects of Conivaptan versus Mannitol on Post-Ischemic Brain Injury and Edema.

Authors:  Betul Can; Semih Oz; Varol Sahinturk; Ahmet Musmul; İbrahim Ozkan Alatas
Journal:  Eurasian J Med       Date:  2019-02

3.  High dietary salt amplifies osmoresponsiveness in vasopressin-releasing neurons.

Authors:  David I Levi; Joshua C Wyrosdic; Amirah-Iman Hicks; Mary Ann Andrade; Glenn M Toney; Masha Prager-Khoutorsky; Charles W Bourque
Journal:  Cell Rep       Date:  2021-03-16       Impact factor: 9.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.